Flag of the European Union EU Clinical Trials Register Help

Clinical trials for AGI

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    19 result(s) found for: AGI. Displaying page 1 of 1.
    EudraCT Number: 2004-002762-38 Sponsor Protocol Number: Clin-AGI001-001 Start Date*: 2005-04-13
    Sponsor Name:AGI Therapeutics Limited
    Full Title: A randomised, double-blind, placebo-controlled study of AGI 001 in the treatment of functional dyspepsia
    Medical condition: Functional (Non-ulcer) Dyspepsia
    Disease: Version SOC Term Classification Code Term Level
    7.0 10001394 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-000436-24 Sponsor Protocol Number: AGI006-001 Start Date*: 2005-04-08
    Sponsor Name:AGI Therapeutics Limtied
    Full Title: A randomised, double-blind, placebo-controlled study of AGI 006 in the treatment of functional dyspepsia.
    Medical condition: Functional (Non-ulcer) Dyspepsia (FD; NUD)
    Disease: Version SOC Term Classification Code Term Level
    6.0 10013946 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) LT (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002752-34 Sponsor Protocol Number: Clin-AGI003-001 Start Date*: 2004-12-20
    Sponsor Name:AGI Therapeutics Limited
    Full Title: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF AGI 003 IN THE TREATMENT OF NON-CONSTIPATION PREDOMINANT IRRITABLE BOWEL SYNDROME.
    Medical condition: Irritable bowel syndrome (not constipation predominant).
    Disease: Version SOC Term Classification Code Term Level
    7.0 10023003 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002414-39 Sponsor Protocol Number: MK-3102-018 Start Date*: 2013-01-04
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes Mellitus
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    18.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) NL (Prematurely Ended) DE (Completed) NO (Completed) SE (Prematurely Ended) AT (Prematurely Ended) CZ (Completed) ES (Prematurely Ended) FI (Completed) DK (Prematurely Ended) IT (Completed) BE (Completed) SK (Prematurely Ended) LT (Prematurely Ended) PL (Prematurely Ended) FR (Prematurely Ended) HR (Completed)
    Trial results: View results
    EudraCT Number: 2007-004291-39 Sponsor Protocol Number: Clin-AGI004-002 Start Date*: 2008-09-09
    Sponsor Name:AGI Therapeutics Research Ltd
    Full Title: A randomised, multi-centre, double-blind, balanced, parallel group placebo-controlled study of AGI004 for the control of chemotherapy-induced diarrhoea.
    Medical condition: Chemotherapy-induced diarrhoea
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012745 Diarrhoea NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003849-32 Sponsor Protocol Number: AGI003-007 (ARDIS-3) Start Date*: 2007-10-22
    Sponsor Name:AGI Therapeutics Research Ltd
    Full Title: An Open-label, Roll-over Safety Study of AGI-003 (Arverapamil) in the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D)
    Medical condition: Irritable Bowel Syndrome with Diarrhea (IBS-D)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060845 Diarrhea predominant irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PL (Prematurely Ended) CZ (Prematurely Ended) LT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-004230-14 Sponsor Protocol Number: Clin-AGI001-002 Start Date*: 2004-12-22
    Sponsor Name:AGI Therapeutics Limited
    Full Title: A randomised, double-blind, placebo-controlled study of AGI 001 in the treatment of irritable bowel syndrome.
    Medical condition: Irritable Bowel Syndrome
    Disease: Version SOC Term Classification Code Term Level
    6.0 10023003 PT
    Population Age: Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003553-82 Sponsor Protocol Number: AGI003-003 (ARDIS-1) Start Date*: 2007-10-22
    Sponsor Name:AGI Therapeutics Research Ltd
    Full Title: A Randomized, Double-blind, Placebo-controlled Study of AGI-003 (Arverapamil) in the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D)
    Medical condition: Irritable Bowel Syndrome with Diarrhea (IBS-D)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060845 Diarrhea predominant irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005793-63 Sponsor Protocol Number: CLIK066A2202 Start Date*: 2013-10-30
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, randomized, double-blind, double-dummy, parallel-group dose-finding study to evaluate the change in HbA1c after 12 weeks monotherapy with seven doses of LIK066 compared with placebo...
    Medical condition: Type II Diabetes mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) SK (Prematurely Ended) IT (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-024051-93 Sponsor Protocol Number: NN1218-3853 Start Date*: 2013-05-23
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination with Insulin Glargine and Metformin in Adults with Type 2 Diabetes
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2012-005583-10 Sponsor Protocol Number: NN1218-4049 Start Date*: 2013-05-15
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and safety of FIAsp in a basal-bolus regimen versus basal insulin therapy, both in combination with metformin in adult Subjects with type 2 diabetes
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed)
    Trial results: View results
    EudraCT Number: 2007-003723-21 Sponsor Protocol Number: CLAF237A23137 Start Date*: 2007-11-22
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd) versus placebo in patients with type 2 diabetes an...
    Medical condition: Diabetes Type 2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) FR (Completed) ES (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2006-005192-18 Sponsor Protocol Number: A5351022 Start Date*: 2007-03-15
    Sponsor Name:Pfizer Ltd.
    Full Title: A 1-YEAR, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CP-945,598 IN THE TREATMENT OF OVERWEIGHT, ORAL AGENT-TREATED SUBJECTS WITH TYPE 2 DIABET...
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029883 Obesity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) SK (Completed) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005855-35 Sponsor Protocol Number: U1111-1270-0943 Start Date*: 2023-01-10
    Sponsor Name:NOVO NORDISK. S.P.A.
    Full Title: The cardiovascular safety of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once-weekly in participants with obesity and established cardiovascu...
    Medical condition: Atherosclerotic cardiovascular disease and Obesity
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) IE (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) NL (Trial now transitioned) BG (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-001243-18 Sponsor Protocol Number: CLAF237A23137E1 Start Date*: 2008-10-02
    Sponsor Name:Novartis Services AG
    Full Title: A 28 week extension to a 24 week multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of vildagliptin (50 mg qd) versus placebo in patients with type 2 diab...
    Medical condition: Type 2 diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FR (Completed) SE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2012-002603-17 Sponsor Protocol Number: 1218.89 Start Date*: 2013-01-14
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A phase IIIb, multicenter, multinational, randomized, double-blind, placebo controlled, parallel group study to evaluate the glycemic and renal efficacy of once daily administration of linagliptin ...
    Medical condition: Type 2 diabetes patients receiving treatment with ACEi or ARB with micro- or macroalbuminuria (UACR between 30 and 3000 mg/g creatinine). [ACEi=Angiotensin Converting Enzyme inhibitor; ARB=Angioten...
    Disease: Version SOC Term Classification Code Term Level
    18.0 10027433 - Metabolism and nutrition disorders 10027433 Metabolism and nutrition disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FI (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-005121-24 Sponsor Protocol Number: NN9838-4609 Start Date*: 2022-07-26
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly in participants withoverweight or obesityand type 2 diabetes
    Medical condition: Overweight, Obesity and Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    24.1 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    21.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) PL (Trial now transitioned) IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-018411-15 Sponsor Protocol Number: 28431754DIA3010 Start Date*: 2010-07-16
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-Blind, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    12.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) SE (Completed) PL (Completed) ES (Completed) GB (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2019-002481-13 Sponsor Protocol Number: AG881-C-004 Start Date*: 2020-10-27
    Sponsor Name:Institut de Recherches Internationales Servier (I.R.I.S)
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation
    Medical condition: Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018338 Glioma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 09:03:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA